New hope for Hard-to-Treat cancers: drug targets MTAP deletion
NCT ID NCT07492680
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 4 times
Summary
This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BMS-986504 (also called MRTX1719 or Navlimetostat)
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific genetic deletion (MTAP).
- What could go wrong
- This is an early phase 2 trial, so the drug may not work or may cause side effects. It is only for people with a specific tumor marker, so it won't apply to most cancer patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 201321, China
-
Johns Hopkins Hospital
RECRUITINGBaltimore, Maryland, 21287, United States
-
Local Institution - 0004
NOT_YET_RECRUITINGSeoul, Seoul-teukbyeolsi [Seoul], 03080, South Korea
-
Local Institution - 0007
NOT_YET_RECRUITINGToronto, Ontario, M5G 2M9, Canada
-
Local Institution - 0021
NOT_YET_RECRUITINGToronto, Ontario, M4N 3M5, Canada
-
Local Institution - 0022
NOT_YET_RECRUITINGOslo, 0450, Norway
-
Local Institution - 0023
NOT_YET_RECRUITINGDublin, 7, Ireland
-
Local Institution - 0033
NOT_YET_RECRUITINGMadrid, 28028, Spain
-
Local Institution - 0034
NOT_YET_RECRUITINGMilan, 20133, Italy
-
Local Institution - 0039
NOT_YET_RECRUITINGHeidelberg, 69120, Germany
-
Local Institution - 0040
NOT_YET_RECRUITINGHamburg, 20246, Germany
-
Local Institution - 0047
NOT_YET_RECRUITINGWürzburg, 97080, Germany
-
Local Institution - 0049
NOT_YET_RECRUITINGMünchen, 81675, Germany
-
Local Institution - 0050
NOT_YET_RECRUITINGNaples, 80131, Italy
-
Local Institution - 0051
NOT_YET_RECRUITINGVancouver, British Columbia, V2S 0C2, Canada
-
Local Institution - 0052
NOT_YET_RECRUITINGSeoul, Seoul-teukbyeolsi [Seoul], 05505, South Korea
-
Local Institution - 0058
NOT_YET_RECRUITINGSeoul, Seoul-teukbyeolsi [Seoul], 03722, South Korea
-
Local Institution - 0061
NOT_YET_RECRUITINGLeipzig, 04103, Germany
-
Local Institution - 0063
NOT_YET_RECRUITINGShatin, NT, Hong Kong
-
Local Institution - 0068
NOT_YET_RECRUITINGBarcelona, Barcelona [Barcelona], 08035, Spain
-
Local Institution - 0069
NOT_YET_RECRUITINGSeville, 41013, Spain
-
Local Institution - 0071
NOT_YET_RECRUITINGHospitalet, Barcelona [Barcelona], 08907, Spain
-
Local Institution - 0073
NOT_YET_RECRUITINGSiena, Tuscany, 53100, Italy
-
Local Institution - 0074
NOT_YET_RECRUITINGParis, 75010, France
-
Local Institution - 0075
NOT_YET_RECRUITINGPierre-Bénite, Rhône, 69310, France
-
Local Institution - 0078
NOT_YET_RECRUITINGDijon, Côte-d'Or, 21079, France
-
Local Institution - 0080
NOT_YET_RECRUITINGCork, T12 E8YV, Ireland
-
Local Institution - 0081
NOT_YET_RECRUITINGMainz, Rhineland-Palatinate, 55131, Germany
-
Local Institution - 0082
NOT_YET_RECRUITINGPerugia, 06156, Italy
-
Local Institution - 0085
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Local Institution - 0086
NOT_YET_RECRUITINGSeattle, Washington, 98109, United States
-
Local Institution - 0096
NOT_YET_RECRUITINGSan Francisco, California, 94158, United States
-
Local Institution - 0100
NOT_YET_RECRUITINGDurham, North Carolina, 27705, United States
-
Local Institution - 0114
NOT_YET_RECRUITINGGhent, Oost-Vlaanderen, 9000, Belgium
-
Local Institution - 0116
NOT_YET_RECRUITINGVillejuif, Val-de-Marne, 94800, France
-
Local Institution - 0119
NOT_YET_RECRUITINGAnn Arbor, Michigan, 48109-0922, United States
-
Local Institution - 0123
NOT_YET_RECRUITINGBergamo, 24127, Italy
-
Local Institution - 0124
NOT_YET_RECRUITINGBoston, Massachusetts, 02114, United States
-
Local Institution - 0129
NOT_YET_RECRUITINGRochester, Minnesota, 55905, United States
-
Local Institution - 0134
NOT_YET_RECRUITINGMadison, Wisconsin, 53792, United States
-
Local Institution - 0139
NOT_YET_RECRUITINGNew York, New York, 10065, United States
-
Local Institution - 0142
NOT_YET_RECRUITINGBuffalo, New York, 14263, United States
-
Local Institution - 0146
NOT_YET_RECRUITINGDublin, D08 E9P6, Ireland
-
Local Institution - 0148
NOT_YET_RECRUITINGBrussels, Bruxelles-Capitale, Région de, 1200, Belgium
-
Local Institution - 0150
NOT_YET_RECRUITINGHksar, 999077, Hong Kong
-
Local Institution - 0152
NOT_YET_RECRUITINGXinxiang, Henan, 453100, China
-
Local Institution - 0155
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100071, China
-
Local Institution - 0170
NOT_YET_RECRUITINGNew York, New York, 10016, United States
-
Local Institution - 0171
NOT_YET_RECRUITINGBergen, Hordaland, 5021, Norway
-
Local Institution - 0174
NOT_YET_RECRUITINGRochester, Minnesota, 55905, United States
-
Local Institution - 0178
NOT_YET_RECRUITINGAtlanta, Georgia, 30322, United States
-
Local Institution - 0181
NOT_YET_RECRUITINGRochester, Minnesota, 55905, United States
-
Local Institution - 0182
NOT_YET_RECRUITINGAurora, Colorado, 80045, United States
-
Local Institution - 0184
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510060, China
-
Local Institution - 0185
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, 400030, China
-
National Cancer Center Hospital
RECRUITINGChuo-ku, Tokyo, 104-0045, Japan
-
Shanghai GoBroad Cancer Hospital China Pharmaceutical University
RECRUITINGShanghai, Shanghai Municipality, 200131, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Can a Dual-Pronged antibody outsmart advanced solid tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?